Clinical trial
Metabolic Signatures and Biomarkers in Schizophrenia
NCT00466310 · Duke University, Other · Completed
Key facts
| NCT number | NCT00466310 |
|---|---|
| Title | Metabolic Signatures and Biomarkers in Schizophrenia |
| Official title | Metabolic Signatures and Biomarkers in First Episode and Recurrent Patients With Schizophrenia in Comparison to Healthy Controls |
| Lead sponsor | Duke University, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug, Other |
| Interventions | Aripiprazole, Risperidone, Healthy volunteers |
| Enrollment | 71 |
| Start date | Feb 1, 2007 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2011 |
| First posted | Apr 27, 2007 |
| Last update posted | Jul 25, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: